A prospective survey of Streptococcus pyogenes infections in French Brittany from 2009 to 2017: Comprehensive dynamic of new emergent emm genotypes.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
10
2020
accepted:
02
12
2020
entrez:
17
12
2020
pubmed:
18
12
2020
medline:
3
3
2021
Statut:
epublish
Résumé
Streptococcus pyogenes or group A Streptococcus (GAS) causes diseases ranging from uncomplicated pharyngitis to life-threatening infections. It has complex epidemiology driven by the diversity, the temporal and geographical fluctuations of the circulating strains. Despite the global burden of GAS diseases, there is currently no available vaccination strategy against GAS infections. This study, based on a longitudinal population survey, aimed to understand the dynamic of GAS emm types and to give leads to better recognition of underlying mechanisms for the emergence of successful clones. From 2009 to 2017, we conducted a systematic culture-based diagnosis of GAS infections in a French Brittany population with a prospective recovery of clinical data. The epidemiological analysis was performed using emm typing combined with the structural and functional cluster-typing system for all the recovered strains. Risk factors for the invasiveness, identified by univariate analysis, were computed in a multiple logistic regression analysis, and the only independent risk factor remaining in the model was the age (OR for the entire range [CI95%] = 6.35 [3.63, 11.10]; p<0.0001). Among the 61 different emm types identified, the most prevalent were emm28 (16%), emm89 (15%), emm1 (14%), and emm4 (8%), which accounted for more than 50% of circulating strains. During the study period, five genotypes identified as emm44, 66, 75, 83, 87 emerged successively and belonged to clusters D4, E2, E3, and E6 that were different from those gathering "Prevalent" emm types (clusters A-C3 to 5, E1 and E4). We previously reported significant genetic modifications for emm44, 66, 83 and 75 types resulting possibly from a short adaptive evolution. Herein we additionally observed that the emergence of a new genotype could occur in a susceptible population having specific risk factors or probably lacking a naturally-acquired cluster-specific immune cross-protection. Among emergent emm types, emm75 and emm87 tend to become prevalent with a stable annual incidence and the risk of a clonal expansion have to be considered.
Identifiants
pubmed: 33332468
doi: 10.1371/journal.pone.0244063
pii: PONE-D-20-31664
pmc: PMC7746304
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0244063Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Clin Microbiol. 2009 Apr;47(4):1155-65
pubmed: 19158266
N Engl J Med. 1996 Aug 22;335(8):547-54
pubmed: 8684408
Clin Infect Dis. 2007 Oct 1;45(7):853-62
pubmed: 17806049
Clin Infect Dis. 2017 Oct 16;65(9):1523-1531
pubmed: 29020160
BMC Microbiol. 2011 Apr 01;11:65
pubmed: 21457552
J Clin Microbiol. 2015 Jul;53(7):2015-21
pubmed: 25878351
J Infect Dis. 2005 Sep 1;192(5):760-70
pubmed: 16088825
Clin Infect Dis. 2015 Jan 15;60(2):267-70
pubmed: 25313248
Sci Rep. 2015 Jul 15;5:12057
pubmed: 26174161
Eur J Clin Invest. 2012 Jan;42(1):1-16
pubmed: 22023344
Genome Announc. 2016 Jul 21;4(4):
pubmed: 27445380
J Exp Med. 1959 Aug 1;110(2):271-92
pubmed: 13673139
Epidemiol Infect. 2016 Jun;144(8):1770-3
pubmed: 26645633
J Clin Microbiol. 2008 Jul;46(7):2359-67
pubmed: 18463210
Infect Genet Evol. 2015 Jul;33:393-418
pubmed: 25460818
Vaccine. 2017 Jan 3;35(1):19-26
pubmed: 27890396
J Infect Dis. 2000 Oct;182(4):1109-16
pubmed: 10979907
Genome Announc. 2014 Nov 20;2(6):
pubmed: 25414498
Genome Announc. 2015 Jan 22;3(1):
pubmed: 25614568
Clin Infect Dis. 2009 Jul 1;49(1):78-84
pubmed: 19480575
Nature. 1981 Jul 30;292(5822):457-9
pubmed: 6166868
Clin Infect Dis. 2007 Aug 15;45(4):450-8
pubmed: 17638193
Expert Rev Vaccines. 2016;15(2):227-38
pubmed: 26559880
BMC Microbiol. 2008 Apr 11;8:59
pubmed: 18405369
Euro Surveill. 2005 Sep;10(9):179-84
pubmed: 16280610
J Clin Microbiol. 2010 Mar;48(3):842-51
pubmed: 20042624
Arch Pediatr. 2014 Nov;21 Suppl 2:S62-8
pubmed: 25456682
Clin Infect Dis. 2014 Dec 1;59(11):1651-2
pubmed: 25115872
Genome Announc. 2017 Sep 28;5(39):
pubmed: 28963207
Emerg Infect Dis. 2011 Feb;17(2):315-7
pubmed: 21291620
J Clin Microbiol. 2008 Jan;46(1):79-86
pubmed: 17959766
Vaccine. 2008 Oct 29;26(46):5835-42
pubmed: 18789365
mBio. 2015 Jul 14;6(4):e00622
pubmed: 26173696
Clin Microbiol Rev. 2014 Apr;27(2):264-301
pubmed: 24696436
J Clin Microbiol. 1996 Apr;34(4):953-8
pubmed: 8815115
Lancet Infect Dis. 2009 Oct;9(10):611-6
pubmed: 19778763
J Infect Dis. 2014 Oct 15;210(8):1325-38
pubmed: 24799598
Future Microbiol. 2010 Apr;5(4):623-38
pubmed: 20353302
Clin Infect Dis. 2014 Oct;59(7):e84-92
pubmed: 24965347
Am J Reprod Immunol. 2012 Feb;67(2):91-100
pubmed: 22023345
Lancet Infect Dis. 2005 Nov;5(11):685-94
pubmed: 16253886
Eur J Clin Microbiol Infect Dis. 2015 Oct;34(10):2131-6
pubmed: 26292935